Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 408 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Follow-Up Questions
¿Quién es el CEO de Vir Biotechnology Inc?
Dr. Marianne De Backer es el Chief Executive Officer de Vir Biotechnology Inc, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción VIR?
El precio actual de VIR es de $5.79, ha increased un 0.17% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Vir Biotechnology Inc?
Vir Biotechnology Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Vir Biotechnology Inc?
La capitalización bursátil actual de Vir Biotechnology Inc es $804.3M
¿Es Vir Biotechnology Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 10 analistas han realizado calificaciones de análisis para Vir Biotechnology Inc, incluyendo 3 fuerte compra, 9 compra, 1 mantener, 0 venta, y 3 fuerte venta
